Trinity Biotech
TRIB
25 hedge funds and large institutions have $10.8M invested in Trinity Biotech in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 7 closing their positions.
0% less ownership
Funds ownership: 0.07% → 0.07% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
11% less funds holding
Funds holding: 28 → 25 (-3)
16% less capital invested
Capital invested by funds: $12.9M → $10.8M (-$2.1M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Fondren Management
Houston,
Texas
|
+$208K |
| 2 |
SCM
Stonehill Capital Management
New York
|
+$133K |
| 3 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$89.6K |
| 4 |
Renaissance Technologies
New York
|
+$6.42K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$884K |
| 2 |
FWSM
First Wilshire Securities Management
Pasadena,
California
|
-$232K |
| 3 |
State Street
Boston,
Massachusetts
|
-$142K |
| 4 |
ARM
Adirondack Research & Management
Guilderland,
New York
|
-$59.5K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$15K |
TRIB Hedge Fund Activity: Q4 2019 in Review
25 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q4 2019, worth a combined $10.8M — down 16% from $12.9M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TRIB and 4 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Fondren Management, adding an estimated $208K. The largest seller was Janus Henderson Group, exiting entirely with an estimated $884K sold.
- 25 institutional investors held Trinity Biotech (TRIB) as of Q4 2019, down from 28 in Q3 2019.
- Funds reported $10.8M of Trinity Biotech stock for Q4 2019, down 16% quarter-over-quarter.
- 4 funds opened new Trinity Biotech positions in Q4 2019 and 7 closed out, a net change of -3 holders.
- The largest Trinity Biotech buyer in Q4 2019 was Fondren Management, an estimated $208K added.
- The largest Trinity Biotech seller in Q4 2019 was Janus Henderson Group, an estimated $884K sold.
Based on aggregated 13F filings for Q4 2019.